Company
Path
Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
5
510(k), De Novo and PMA
Device trials
16
As lead sponsor, any status
Adverse event reports
0
Received Nov 1, 2025 to Nov 19, 2026
Recall records
13
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
From SEC filings.
We found no SEC financing filings under the name Path, so its financing is unknown here. That is common for companies based outside the US, for subsidiaries of larger companies, and for companies funded by founders, grants or customers. A company that changed its name can also be missed.
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Path.
Latest FDA decisions
K242492 · Decided Dec 30, 2025 · 496 days after receipt
Device type: Assayed Quality Control Material For Clinical Microbiology Assays (QCH) · Laboratory Medicine & Pathology
- QScreen510(k)
K220139 · Decided Aug 3, 2022 · 197 days after receipt
Device type: Stimulator, Auditory, Evoked Response (GWJ) · Neurology & Neurosurgery
K213345 · Decided Jun 22, 2022 · 257 days after receipt
Device type: Audiometer (EWO) · Otolaryngology (ENT)
2 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
NCT05621876 · 50 participants · Start May 15, 2024 · Primary completion Sep 1, 2024
Device: IgG deficiency rapid screening test · For: Primary Immunodeficiency Diseases
Sites: Tunis, Tunisia
NCT05758506 · 200 participants · Start Jul 1, 2024 · Primary completion Sep 30, 2024
Device: Primary Immunodeficiency (PID) Rapid Diagnostic Test (RDT) · For: Primary Immunodeficiency Diseases
Sites: Karachi, Pakistan
- Initial Feasibility Study of the CycloPE® DeviceActive, not recruiting
NCT06970899 · 15 participants · Start Jun 11, 2024 · Primary completion Apr 26, 2025
Device: PATH EX CycloPE® Device · For: Sepsis; Infection; Bacteremia Sepsis and 1 more
Sites: Yerevan, Armenia
13 more trials with a free account
Reports received
0
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 1 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 0 | 0 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 0 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 0 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 0 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 0 | 0 | 0 | 0 |
| Jul 26 | 0 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 0 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
No device types to rank.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
No brand names to rank.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Techno-Path Multichem AE Unassayed Level 1 REF:AE621XOpen, Classified
Z-0205-2027 · Started Aug 14, 2026 · Posted by FDA Oct 22, 2026
Reason given: A routine stability studies have identified a stability drift affecting the Ammonia (NH4+) analyte in specific lots of Multichem AE quality control material. Additional testing confirmed that the labelled shelf-life performance claim for the Ammonia analyte can no longer be supported for the affected lots. This issue...
Cause as FDA categorized it: Under Investigation by firm · Device type: Multi-Analyte Controls Unassayed (OHQ)
- Techno-Path Multichem AE Unassayed Level 2 REF: AE622XOpen, Classified
Z-0206-2027 · Started Aug 14, 2026 · Posted by FDA Oct 22, 2026
Reason given: A routine stability studies have identified a stability drift affecting the Ammonia (NH4+) analyte in specific lots of Multichem AE quality control material. Additional testing confirmed that the labelled shelf-life performance claim for the Ammonia analyte can no longer be supported for the affected lots. This issue...
Cause as FDA categorized it: Under Investigation by firm · Device type: Multi-Analyte Controls Unassayed (OHQ)
- Techno-Path Multichem AE Unassayed Level 3, REF:AE623XOpen, Classified
Z-0207-2027 · Started Aug 14, 2026 · Posted by FDA Oct 22, 2026
Reason given: A routine stability studies have identified a stability drift affecting the Ammonia (NH4+) analyte in specific lots of Multichem AE quality control material. Additional testing confirmed that the labelled shelf-life performance claim for the Ammonia analyte can no longer be supported for the affected lots. This issue...
Cause as FDA categorized it: Under Investigation by firm · Device type: Multi-Analyte Controls Unassayed (OHQ)
10 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.